CLDF Title
Home | Contact Us | Bookmark
About CLDF Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Conference Highlights
Reuters Health Information (2003-08-04): Hepatitis B virus reactivation common during breast cancer chemotherapy


Hepatitis B virus reactivation common during breast cancer chemotherapy

Last Updated: 2003-08-04 13:26:53 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Hepatitis B virus (HBV) reactivation may complicate cytotoxic chemotherapy used in the treatment of breast cancer, according to a report in the August Journal of Medical Virology.

HBV reactivation is a well-recognized phenomenon in patients treated for hematological malignancies, the authors explain, but limited information about HBV reactivation is available for patients with breast cancer.

Dr. Winnie Yeo and colleagues from Chinese University of Hong Kong followed 41 breast cancer patients found to be HBsAg-positive at baseline through their course of chemotherapy for HBV reactivation using conventional monitoring and serial HBV DNA monitoring.

Ten of the 41 patients (24%) developed clinical HBV reactivation during cytotoxic chemotherapy for breast cancer, the authors report. Seven more patients were diagnosed by the detection of HBV DNA.

All 17 patients with HBV reactivation had normalization of function after treatment with lamivudine. No patient died as a result of HBV reactivation.

HBV reactivation prompted premature termination of chemotherapy in 6 women and a delay of at least 1 week in completing chemotherapy in 6 other women. "Thus, the researchers note, "overall 12 of the 17 patients (71%) who developed HBV reactivation, as compared with 8 of the 24 patients (33%) who did not develop the condition, suffered premature discontinuation/delay of chemotherapy."

No risk factors could be identified to distinguish women who developed HBV reactivation from those who did not develop HBV reactivation.

"In a common disease such as breast cancer, in which combination chemotherapy is an important modality of therapy," the authors conclude, "HBV reactivation constitutes a major cause of chemotherapy-related hepatic morbidity in HBsAg-seropositive subjects."

"Regular monitoring with HBV DNA in addition to ALT during the immunosuppressed period may enable early detection of the condition and facilitate prompt antiviral therapy when a predetermined threshold of HBV DNA is reached, prior to hepatic inflammation and destruction," the investigators write.

"Alternatively," where HBV DNA assays are not available, "the prophylactic use of an antiviral drug in all patients before and throughout chemotherapy is being considered."

J Med Virol 2003;70:553-561.

Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
Abstract Library
Slide Library
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Sponsors & Supporters
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
Centers of
Educational Expertise
Substance Use Disorder
CLDF Follow Us
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2018 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.